Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Phenylketonuria · Achondroplasia

BioMarin Pharmaceutical Australia

BioMarin Pharmaceutical Australia Pty Ltd

BioMarin Pharmaceutical Australia clinical programs — 41 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
770 Lindaro Street, San Rafael, CA 94901, US HQ
1997 Founded
3,171 Employees
TGA registrant Type
Company details
Status
Public
HQ
770 Lindaro Street, San Rafael, CA 94901, US
Founded
1997
Employees
3,171
Programs
91
Drugs
36
Patents
175
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

BioMarin Pharmaceutical Australia projects

41 ClinicalTrials.gov programs sponsored by BioMarin Pharmaceutical Australia.

BioMarin Pharmaceutical Australia has 41 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

41 programs

Clinical programs

  1. 111-205

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 small molecule active

    1 trial

  2. 111-208

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 small molecule active

    1 trial

  3. 111-210

    BioMarin Pharmaceutical Australia Pty Ltd

    Idiopathic Short Stature (ISS)

    phase 2 small molecule active

    1 trial

  4. 111-211

    BioMarin Pharmaceutical Australia Pty Ltd

    Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome

    phase 2 small molecule active

    1 trial

  5. 111-212

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypochondroplasia

    phase 2 small molecule active

    1 trial

  6. 6R BH4

    BioMarin Pharmaceutical Australia Pty Ltd

    Kidney Disease

    phase 2 small molecule completed

    1 trial

  7. 6R-BH4

    BioMarin Pharmaceutical Australia Pty Ltd

    Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  8. 6R-BH4

    BioMarin Pharmaceutical Australia Pty Ltd

    Isolated Systolic Hypertension

    phase 2 small molecule terminated

    1 trial

  9. 6R-BH4 (sapropterin dihydrochloride)

    BioMarin Pharmaceutical Australia Pty Ltd

    Hypertension

    phase 2 small molecule completed

    1 trial

  10. BMN 044 IV 6 mg/kg

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  11. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    MPS IV A

    phase 2 small molecule terminated

    2 trials

  12. BMN 110

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis IVA

    phase 2 small molecule terminated

    3 trials

  13. BMN 165 (rAvPAL-PEG)

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 2 mab completed

    1 trial

  14. BMN 190

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    2 trials

  15. BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1)

    BioMarin Pharmaceutical Australia Pty Ltd

    Jansky-Bielschowsky Disease

    phase 2 mab completed

    1 trial

  16. BMN 307

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria (PKU)

    phase 2 small molecule active

    1 trial

  17. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  18. BMN 351

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy (DMD)

    phase 2 small molecule active

    1 trial

  19. BMN 701

    BioMarin Pharmaceutical Australia Pty Ltd

    Pompe Disease

    phase 2 mab completed

    2 trials

  20. Dose 1 of BMN 331

    BioMarin Pharmaceutical Australia Pty Ltd

    Hereditary Angioedema

    phase 2 gene therapy active

    1 trial

  21. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  22. Exon 51 specific phosphorothioate oligonucleotide

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule active

    1 trial

  23. PRO044 SC

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule completed

    1 trial

  24. PRO044 SC 6 mg/kg

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  25. PRO045, 0.15 mg/kg/week

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  26. Phenoptin

    BioMarin Pharmaceutical Australia Pty Ltd

    Tetrahydrobiopterin Deficiencies

    phase 2 small molecule completed

    1 trial

  27. Regimen Selection Phase Group 2

    BioMarin Pharmaceutical Australia Pty Ltd

    Duchenne Muscular Dystrophy

    phase 2 small molecule terminated

    1 trial

  28. Sapropterin

    BioMarin Pharmaceutical Australia Pty Ltd

    GTP Cyclohydrolase Deficiency

    phase 2 small molecule completed

    1 trial

  29. Sapropterin

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 2 small molecule terminated

    1 trial

  30. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Sickle Cell Disease

    phase 2 small molecule completed

    1 trial

  31. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Endothelial Dysfunction

    phase 2 small molecule completed

    1 trial

  32. Sapropterin Dihydrochloride

    BioMarin Pharmaceutical Australia Pty Ltd

    Intermittent Claudication

    phase 2 small molecule completed

    1 trial

  33. Talazoparib Tosylate

    BioMarin Pharmaceutical Australia Pty Ltd

    Advanced Breast Cancer

    phase 2 small molecule completed

    1 trial

  34. Valoctocogene roxaparvovec

    BioMarin Pharmaceutical Australia Pty Ltd

    Hemophilia A With Inhibitor

    phase 2 mab active

    1 trial

  35. Vosoritide Injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Idiopathic Short Stature

    phase 2 small molecule active

    1 trial

  36. Vosoritide Injection

    BioMarin Pharmaceutical Australia Pty Ltd

    Noonan Syndrome

    phase 2 small molecule active

    1 trial

  37. rAvPAL-PEG

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 2 small molecule completed

    3 trials

  38. rAvPAL-PEG 0.001 mg/kg

    BioMarin Pharmaceutical Australia Pty Ltd

    Phenylketonuria

    phase 2 small molecule completed

    1 trial

  39. sapropterin

    BioMarin Pharmaceutical Australia Pty Ltd

    Autistic Disorder

    phase 2 small molecule completed

    1 trial

  40. valoctocogene roxaparvovec

    BioMarin Pharmaceutical Australia Pty Ltd

    Severe Haemophilia A

    phase 2 mab completed

    1 trial

  41. vosoritide

    BioMarin Pharmaceutical Australia Pty Ltd

    Achondroplasia

    phase 2 mab active

    1 trial

Frequently asked questions

How many clinical projects does BioMarin Pharmaceutical Australia have?

41 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.